In vitro and in vivo characterization of a novel negative allosteric modulator of neuronal nAChRs.

Neuropharmacology
Galya R AbdrakhmanovaF Ivy Carroll

Abstract

In this study, we compared the in vitro and in vivo neuronal nicotinic acetylcholine receptor (nAChR) properties of 1,2,3,3a,4,8b-hexahydro-2-benzyl-6-N,N-dimethylamino-1-methylindeno[1,2,-b]pyrrole (HDMP, 4) to that of negative allosteric modulator (NAM), PCP. Patch-clamp experiments showed that HDMP exhibited an inhibitory functional activity at α7 nAChRs with an IC(50) of 0.07 μM, and was 357- and 414-fold less potent at α4β2 and α3β4 nAChRs, with IC(50)s of 25.1 and 29.0 μM, respectively. Control patch-clamp experiments showed that PCP inhibited α7, α4β2 and α3β4 nAChRs with IC(50)s of to 1.3, 29.0 and 6.4 μM, respectively. Further, HDMP did not exhibit any appreciable binding affinity to either α7 or α4β2 nAChRs, suggesting its action via a non-competitive mechanism at these neuronal nAChR subtypes. The in vivo study showed that HDMP was a potent antagonist of nicotine-induced analgesia in the tail-flick (AD(50)=0.008 mg/kg), but not in the hot-plate test. All together, our in vitro and in vivo data suggest that HDMP is a novel NAM of neuronal nAChRs with potent inhibitory activity at α7 nAChR subtype at concentrations ≤ 1μM that are not effective for α4β2 and α3β4 nAChRs.

References

Jan 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·P Whiting, J Lindstrom
Oct 16, 1999·Proceedings of the National Academy of Sciences of the United States of America·C LénaJ P Changeux
Dec 29, 2000·Bioorganic & Medicinal Chemistry Letters·G FerrettiR A Glennon
May 16, 2003·Proceedings of the National Academy of Sciences of the United States of America·Jonathan R Genzen, Daniel S McGehee
Mar 16, 2004·The Journal of Pharmacology and Experimental Therapeutics·Yingxian Xiao, Kenneth J Kellar
Jan 22, 2005·Current Opinion in Pharmacology·Brian J MorrisJudith A Pratt
Mar 8, 2006·The International Journal of Biochemistry & Cell Biology·Hugo R AriasCecilia Bouzat
Dec 29, 2006·Journal of Molecular Neuroscience : MN·Katrin Susanne LipsWolfgang Kummer
Aug 21, 2007·Biochemical Pharmacology·Daniel Bertrand, Murali Gopalakrishnan
Sep 18, 2007·The Journal of Pharmacology and Experimental Therapeutics·Ryan F YoshimuraKelvin W Gee
Oct 19, 2007·Journal of Neurophysiology·J Russel KeathDaniel S McGehee
Feb 12, 2008·Trends in Molecular Medicine·Jean-Pierre Changeux, Antoine Taly
Jan 20, 2009·American Journal of Respiratory and Critical Care Medicine·Laura PaleariMassimo Fini

❮ Previous
Next ❯

Citations

Nov 4, 2017·Pharmacology & Therapeutics·Laura HondebrinkRemco H S Westerink
Jun 1, 2021·Journal of Molecular Graphics & Modelling·Osama I AlwassilMałgorzata Dukat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.